Heart failure & cardiomyopathiesTrial design
Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design
- randomized, placebo-controlled, double-blind, multi-centre, dose-ranging study
- Phase 2b
Study context
- Population
- Participants with chronic heart failure (HF), left ventricular ejection fraction (LVEF) ≤35% (Cohort A) or LVEF 41%-55% (Cohort B)planned enrolment · Cohort A (LVEF ≤35%) 220 · Cohort B (LVEF 41%-55%) 140
- Participants
- ∼360 participants
- Planned comparison
- three once daily oral doses of AZD5462 or placebo for 24 weeks
- Primary endpoint
- changes in end-systolic volume index (Cohort A) and systemic vascular resistance index (Cohort B)
- Follow-up
- After 24 weeks
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design. ESC Heart Fail. Published 8 January 2026. doi:10.1093/eschf/xvaf007
Summarised from the published abstract; every number is checked against it